[
IHC PSMA expression
[177Lu]Lu-PSMA therapy
[68Ga]Ga-PSMA PET/MRI
individualized treatment
relapsing malignant glioma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
06
2022
accepted:
25
07
2022
entrez:
19
9
2022
pubmed:
20
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
High-grade gliomas (HGG) are still associated with a dismal prognosis. Prostate specific membrane antigen (PSMA) is discussed as a theranostic target for PSMA-directed radioligand therapy ([ Patients with relapsing HGG underwent [ We included 20 patients with a median age of 53 years (IQR 42-57). The median SUV on [ Only a minority of patients with relapsing HGG qualified for [
Identifiants
pubmed: 36119502
doi: 10.3389/fonc.2022.980058
pmc: PMC9478729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
980058Informations de copyright
Copyright © 2022 Truckenmueller, Graef, Scheel, Vajkoczy, Capper, Kaul, Furth, Amthauer, Brenner and Onken.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Cell Int. 2014 Mar 20;14(1):26
pubmed: 24645697
J Neurooncol. 2018 Jul;138(3):581-589
pubmed: 29524126
J Nucl Med. 2018 Feb;59(2):238-243
pubmed: 28775203
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):170-1
pubmed: 25293865
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544
pubmed: 31440799
Nucl Med Commun. 2017 Jan;38(1):91-98
pubmed: 27782913
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Nucl Med. 2017 Jul;58(7):1017-1018
pubmed: 28408527
Clin Nucl Med. 2020 Dec;45(12):e512-e513
pubmed: 32558721
Clin Nucl Med. 2017 Jan;42(1):e41-e48
pubmed: 27846000
Arch Pathol Lab Med. 2011 Nov;135(11):1486-9
pubmed: 22032578
Neuroradiology. 2022 May;64(5):969-979
pubmed: 34648046
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Front Oncol. 2021 Mar 30;11:646387
pubmed: 33859946
Clin Nucl Med. 2018 Sep;43(9):e304-e309
pubmed: 29939953
Iran J Pathol. 2018 Winter;13(1):45-53
pubmed: 29731795
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1605-1606
pubmed: 32040612
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
J Pers Med. 2021 Jun 30;11(7):
pubmed: 34209106
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
J Clin Pathol. 2001 Dec;54(12):956-60
pubmed: 11729217
Clin Nucl Med. 2020 Jan;45(1):11-18
pubmed: 31663868
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Clin Nucl Med. 2019 May;44(5):e318-e322
pubmed: 30829867
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
J Nucl Med. 2021 Sep 1;62(9):1242-1243
pubmed: 34272320
Lung Cancer. 2013 Nov;82(2):231-7
pubmed: 23972450
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
Front Cell Dev Biol. 2021 Mar 04;9:598377
pubmed: 33748101
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541